Patents Assigned to NANOVI RADIOTHERAPY APS
  • Patent number: 11331396
    Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: May 17, 2022
    Assignees: TECHNICAL UNIVERSITY OF DENMARK, NANOVI RADIOTHERAPY APS
    Inventors: Thomas Andresen, Rasmus Irming Jølck, Linda Maria Bruun
  • Patent number: 11058780
    Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 13, 2021
    Assignees: TECHNICAL UNIVERSITY OF DENMARK, NANOVI RADIOTHERAPY APS
    Inventors: Thomas Lars Andresen, Rasmus Irming Jølck, Linda Maria Bruun
  • Publication number: 20200197541
    Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.
    Type: Application
    Filed: January 2, 2020
    Publication date: June 25, 2020
    Applicants: DANMARKS TEKNISKE UNIVERSITET, NANOVI RADIOTHERAPY APS
    Inventors: Thomas Lars Andresen, Rasmus Irming Jolck, Morten Albrechtsen
  • Patent number: 10561746
    Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: February 18, 2020
    Assignees: Danmarks Tekniske Universitet, Nanovi Radiotherapy APS
    Inventors: Thomas Lars Andresen, Rasmus Irming Jolck, Morten Albrechtsen
  • Publication number: 20190275174
    Abstract: The present invention relates to a palpable marker composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 50,000 centipoise (cP) after administration, for use for identifying and/or locating a non palpable tumor. In one embodiment the composition the composition is a liquid before administration into the human or animal body that increases in viscosity by more than 500,000 centipoise (cP) after administration into the human or animal body.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 12, 2019
    Applicants: TECHNICAL UNIVERSITY OF DENMARK, NANOVI RADIOTHERAPY APS
    Inventors: Thomas Lars Andresen, Rasmus Irming Jølck, Linda Maria Bruun
  • Publication number: 20160089454
    Abstract: The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.
    Type: Application
    Filed: May 23, 2014
    Publication date: March 31, 2016
    Applicants: DANMARKS TEKNISKE UNIVERSITET, NANOVI RADIOTHERAPY APS
    Inventors: Thomas Lars Andresen, Rasmus Irming Jolck, Morten Albrechtsen